Farkowski MM, Maciąg A, Żurawska M, et al. Rapid pharmacological cardioversion of recentonset atrial fibrillation using antazoline in elderly patients. Pol Arch Intern Med. 2022; 132: 16120. doi:10.20452/pamw.16120

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Clinical outcomes of antazoline, ≥ 75 vs < 75 years old in females.

	Antazoline		OR [95% CI]	P-value
	≥75 years old	<75 years old		
	n=41 (6.9%)	n=70 (63.1%)		
Conversion to sinus	29 (70.7%)	50 (71.4%)	0.97 (0.41 - 2.26)	0.94
Discharge	34 (82.9%)	58 (82.9%)	1.00 (0.36 - 2.80)	0.99
Hospitalization AF	6 (15.0%)	12 (17.1%)	0.83 (0.29 – 2.41)	0.73
Hospitalization AE	1 (2.5%)	2 (2.9%)	0.85 (0.07 – 9.697	1.00
Hospitalization (other)	3 (7.3%)	0 (0.0%)	12.8 (0.63 – 261)*	0.048
SBP <100mmHg	1 (2.4%)	0 (0.0%)	5.2 (0.20 – 135)*	0.37
Bradyarrhythmia	5 (12.2%)	6 (8.6%)	1.48 (0.42 – 4.37)	0.53

OR- odds ratio; AE, adverse events; AF, atrial fibrillation; SBP, systolic blood pressure.

^{* -} penalized logistic regression

Table S2. Clinical outcomes of antazoline, \geq 75 vs <75 years old in males.

	Antazoline		OR [95% CI]	P-value
	≥75 years old	<75 years old		
	n=69	n=154 (69.1%)		
	(30.9%)			
Conversion to sinus	57 (82.6%)	103 (66.9%)	2.35 (1.16 - 4.77)	0.02
Discharge	59 (85.5%)	122 (79.2%)	1.55 (0.71 - 3.36)	0.27
Hospitalization AF	10 (14.5%)	28 (18.2%)	0.76 (0.35 – 1.67)	0.49
Hospitalization AE	0 (0%)	7 (4.5%)	0.14 [0.08 - 2.56)*	0.10
Hospitalization (other)	1 (1.4%)	2 (1.3%)	1.12 (0.10 – 12.5)	1.00
SBP <100mmHg	1 (1.4%)	4 (2.6%)	0.55 (0.06 - 5.03)	1.00
Bradyarrhythmia	5 (7.2%)	16 (10.4%)	0.67 (0.24 – 1.92)	0.46

OR- odds ratio; AE, adverse events; AF, atrial fibrillation; SBP, systolic blood pressure.
* - penalized logistic regression

Table S3. Clinical outcomes of antazoline in females vs. males ≥ 75 years old.

	Antazoline		OR [95% CI]	P-value
	Female	Male		
	N=41(37.3%)	N=69 (62.7%)		
Conversion to sinus	29 (70.7%)	57 (82.6%)	0.51 (0.20 - 1.27)	0.14
Discharge	34 (82.9%)	59 (85.5%)	0.82 (0.29 – 2.36)	0.72
Hospitalization AF	6 (14.6%)	10 (14.5%)	1.01 (0.34 – 3.02)	0.94
Hospitalization AE	1 (2.4%)	0 (0%)	5.15 (0.20 – 133) *	0.37
Hospitalization (other)	3 (7.3%)	1 (1.4%)	5.37 (0.54 – 53.4)	0.14
SBP <100mmHg	1 (2.4%)	1 (1.4%)	1.70 (0.10 – 27.93)	1.00
Bradyarrhythmia	5 (12.2%)	5 (7.2%)	1.78 (0.48 – 6.56)	0.49

OR – odds ratio; AE, adverse events; AF, atrial fibrillation; SBP, systolic blood pressure. * - penalized logistic regression

Table S4. Clinical outcomes of antazoline in females vs. males < 75 years old.

	Antazoline		OR [95% CI]	P-value
	Female	Male		
	N=70 (13.2%)	N=154 (68.8%)		
Conversion to sinus	50 (71.4%)	103 (66.9%)	1.24 (0.67 - 2.30)	0.49
Discharge	58 (82.9%)	122 (79.2%)	1.27 (0.61 - 2.64)	0.52
Hospitalization AF	12 (17.1%)	27 (18.2%)	0.93 (0.44 – 1.96)	0.85
Hospitalization AE	2 (2.9%)	7 (4.5%)	0.62 (0.12 – 3.05)*	0.72
Hospitalization (other)	0 (0.0%)	2 (1.3%)	0.43 (0.02 – 9.31)*	1.00
SBP <100mmHg	0 (0.0%)	4 (2.6%)	0.24 (0.01 – 4.55)	0.31
Bradyarrhythmia	6 (8.6%)	16 (10.4%)	0.81 (0.30 – 2.16)	0.67

OR – odds ratio; AE, adverse events; AF, atrial fibrillation; SBP, systolic blood pressure.
* - penalized logistic regression

Table S5. Odds ratios [95% CI] for potential predictors of successful cardioversion (dependent variable) . Results of univariable logistic regression.

Potential predictors	OR [95% CI]	P-Value
Age>75 vs < 75	1.66 [0.976 - 2.83]	0.06
Sex (Male)	1.03 [0.622 – 1.70]	0.91
CAD	2.70 [1.592 – 4.57]	<0.001
PCI history	2.53 [1.089 – 5.86]	0.031
CABG history	2.52 [1.141 – 5.58]	0.02
Hypertension	1.57 [0.972 – 2.54]	0.06
Diabetes mellitus	1.46 [0.749 – 2.86]	0.26
Thyroid disorders	0.73 [0.328 – 1.64]	0.45
Structural heart disease	1.37 [0.749 – 2.51]	0.31
AFL	0.62 [0.313 – 1.24]	0.18
AT	0.14 [0.036 – 0.53]	0.004
PVC	5.85 [0.758 – 45.11]	0.09
SSS	1.52 [0.809 – 2.85]	0.19
AVB		
None	Reference	
AVB I°	1.494 [0.209 – 10.657]	- 0.760
	1	

AVB II°	3.667 [0.139 – 97.004]	
AVB III°	0.407 [0.025 – 6.576]	
Chronic AAD	1.47 [0.74 – 2.94]	0.27

AAD, antiarrhythmic drug; AFL, atrial flutter; AT, atrial tachycardia; AVB, atrioventricular block; CABG, coronary artery bypass graft; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; PCI, percutaneous coronary intervention; PM, pacemaker; PVC, premature ventricular contraction; SSS, sick sinus syndrome.

Table S6. Independent predictors of successful cardioversion. Results of backward multivariable logistic regression analysis. AUC [95% CI]: 0.662 [0.600 – 0.723].

Independent predictors	OR [95% CI]	P-Value
AT (yes vs no)	0.20 [0.05-0.78]	0.021
CAD vs no CAD for Females*	0.95 [0.36-2.49]	0.018
CAD vs no CAD for Males*	3.90 [2.02-7.51]	

^{*} A different effect of coronary artery disease has been demonstrated in men and women with p-value for interaction=0.018. P-value for factor sex was 0.07, and p-value for factor CAD was 0.92. With zero-one encoding and the following designation of the linear predictor coefficients: $\beta_0 + \beta_1$ *Males + β_2 *CAD + β_3 *AT + β_4 * (Males*CAD) , odds ratio for "CAD vs no CAD for Females" is: exp(β_2) and odds ratio for "CAD vs no CAD for Males" is: exp(β_2 + β_4). We found it not interesting to present the odds ratios of, for example, CAD+ men to CAD- women, or CAD+ women to CAD- men.

Table S6A. Independent predictors of successful cardioversion. Results of backward multivariable logistic regression analysis. Model without interaction. AUC [95% CI]: 0.635 [0.578 - 0.691].

Independent predictors	OR [95% CI]	P-Value
AT (yes vs no)	0.177 [0.045 - 0.692]	0.013
CAD (yes vs no)	2.511 [1.473 - 4.218]	<0.001

Table S6B. Independent predictors of successful cardioversion in a group of men. Results of backward multivariable logistic regression analysis. Model without interaction. AUC [95% CI]: 0.696 [0.631 - 0.762].

Independent predictors	OR [95% CI]	P-Value
Structural heart disease (yes vs no)	0.289 [0.098 - 0.847]	0.024
CAD (yes vs no)	8.803 [3.271 – 23.694]	<0.001

In the group of women, the effectiveness of cardioversion cannot be predicted based on the collected data.